NIH cuts billions in funding for medical research
The Trump administration in the US has announced plans to cut billions of dollars in funding for costs related to medical research funding in universities, hospitals and other scientific institutions.
These grants include payments for “indirect costs,” defined as “facilities” and “administration”, which cost up to $9 billion per year.
In an update to its current policies, the National Institutes for Health (NIH) said: “The United States should have the best medical research in the world. It is accordingly vital to ensure that as many funds as possible go towards direct scientific research costs rather than administrative overhead. NIH is accordingly imposing a standard indirect cost rate on all grants of 15%.”
However, many are concerned about the reduction in funding. In a statement, Matt Owens, president of the Council on Government Relations, which represents universities and academic medical centres, said: “This is a surefire way to cripple lifesaving research and innovation. Reimbursement of facilities and administrative expenditures are part and parcel of the total costs of conducting world-class research. America’s competitors will relish this self-inflicted wound. We urge NIH leaders to rescind this dangerous policy before its harms are felt by Americans.”
The NIH spent more than $35 billion in 2023 on around 50,000 grants to more than 300,000 researchers at more than 2,500 universities, medical schools, and other research institutions.
It justifies the cut by pointing out that “private foundations that fund research provide substantially lower indirect costs than the federal government” and many foundations do not fund indirect costs at all.
The update says that indirect costs are “not readily assignable to the cost objectives specifically benefitted” and are therefore difficult to oversee.
The American Society of Gene and Cell Therapy (ASGCT) also issued a statement, which concludes: “Cuts to NIH-covered indirect costs would devastate the infrastructure and support that is critical for research at universities and institutions across the United States. We urge Congress to reaffirm their prior commitment to continue the current indirect costs arrangement and for the administration to abide by those Congressional actions. In this way, the United States will continue to ensure the development of safe and effective new medicines for everyone.”
The move follows the President’s order for the US to withdraw from the World Health Organization in a significant shake-up of government organisations and investment since his inauguration in mid-January.
Diana Spencer, Senior Digital Content Editor, DDW
